Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial - Concepedia

Concepedia

Publication | Open Access

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial

DOI Full Paper Access

51

Citations

18

References

2015

Year

Kazuhiro Nishikawa, Kazumasa Fujitani, Hitoshi Inagaki, Yusuke Akamaru, Shinya Tokunaga, Masakazu Takagi, Shigeyuki Tamura, Naotoshi Sugimoto, Tadashi Shigematsu, Takaki Yoshikawa,

European Journal of Cancer

Abstract

No survival benefit was observed upon adding CDDP to CPT-11 after S-1 monotherapy failure.

References

	Year	Citations

Page 1